Research & Development

The global pharmaceutical landscape has undergone a profound shift as the focus moves from mass-produced chemical pills toward highly personalized, biologically derived treatments that can essentially reprogram a patient’s own immune system. Ireland has positioned itself at the absolute center of

The depths of the ocean have long remained one of the final frontiers for medical innovation, harboring biological secrets that could redefine how modern medicine approaches the most aggressive forms of human malignancy. In a landmark study involving researchers from the Tokyo University of

The long-standing clinical assumption that any distant spread of pancreatic ductal adenocarcinoma necessitates an immediate transition to palliative measures is currently being challenged by a revolutionary shift toward aggressive, curative-intent interventions. Historically, a metastatic diagnosis

The medical community has long recognized that a diagnosis of pancreatic cancer carries an alarmingly high risk of venous thromboembolism, often complicating an already dire prognosis. For years, the development of these life-threatening blood clots was dismissed as a secondary symptom or a mere

The landscape of Spinal Muscular Atrophy treatment has undergone a radical transformation over the past decade, yet the search for more durable and convenient therapies remains a top priority for researchers and families alike. Biogen, a pioneer in the space with the introduction of Spinraza, is

Ivan Kairatov is a seasoned biopharma expert with a distinguished background in research and development, focusing specifically on the intersection of immunology and biotechnology. With years of experience analyzing the clinical and commercial trajectories of next-generation therapies, he has